$13,545.27 consulting Payment -- Biogen to Dr. Gregory Evans
Internal Medicine Physician Gregory Evans Receives $13,545 Consulting Fee from Biogen for Rybelsus
This page provides a detailed analysis of a $13,545.27 consulting payment from Biogen to Dr. Gregory Evans. Data is from the CMS Open Payments (Sunshine Act) database.
Payment Details
| Field | Value |
|---|---|
| Amount | $13,545.27 |
| Payment Type | consulting |
| Payment Nature | Consulting Fee |
| Pharmaceutical Company | Biogen |
| Physician | Dr. Gregory Evans |
| NPI Number | 1819150997 |
| Physician Specialty | Internal Medicine |
| Location | City, MO |
| Date of Payment | 2025-10-18 |
| Related Drug/Device | Rybelsus |
| Conflict Assessment | Moderate -- Worth Noting |
AI-Powered Analysis of This Payment
The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.
Biogen made a $13.5K consulting payment to Gregory Evans, a Internal Medicine specialist in City, MO. The payment was associated with Rybelsus. Gregory Evans received a $13,545.27 consulting fee from Biogen on October 18, 2025. The payment was related to consulting services for the drug Rybelsus. This payment represents a significant financial engagement between a physician and a pharmaceutical company.
Patient Guidance: What This Payment Means for You
Patients should be aware that their physicians may receive payments from pharmaceutical companies for consulting services, which could potentially influence prescribing decisions. Always discuss your treatment options with your healthcare provider and ask about alternatives.
Payment Context: Is This Amount Normal?
Consulting fees for physicians in Internal Medicine can vary widely, but a payment of this size for a single engagement may be higher than average for routine consulting.
Regulatory Context: Sunshine Act Requirements
Payments to physicians from pharmaceutical companies are subject to disclosure under the Open Payments program to ensure transparency in healthcare.
Related Topics
This payment is related to the following healthcare transparency topics:
- pharmaceutical-payments
- physician-compensation
- consulting-fees
- biogen
- rybelsus
- internal-medicine
Understanding consulting Payments
Consulting payments are made when pharmaceutical companies hire physicians as advisors or consultants. This can include serving on advisory boards, providing expert medical opinions on drug development or marketing strategies, and reviewing clinical data. Consulting is one of the most common forms of pharmaceutical payment to physicians and can range from a few hundred dollars for a brief consultation to tens of thousands of dollars for ongoing advisory relationships.
Frequently Asked Questions About This Payment
What was this $13.5K payment for?
This was a consulting payment of $13.5K from Biogen to Gregory Evans, categorized as "Consulting Fee". It was associated with Rybelsus. The payment was reported under the Sunshine Act (CMS Open Payments).
Does Gregory Evans accept pharmaceutical money?
Yes, Gregory Evans received this $13.5K payment from Biogen. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Gregory Evans's full payment history on the CMS Open Payments database or on this site.
Is it legal for doctors to accept pharma payments?
Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.
Should I be concerned about this consulting payment?
A consulting payment of $13.5K may reflect legitimate advisory services the physician provides. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.
How do I talk to my doctor about pharma relationships?
You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.
What types of pharma payments are most concerning?
Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.
Does pharma money affect what my doctor prescribes?
Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.
How does this compare to other doctors in Internal Medicine?
To compare this payment against Internal Medicine averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Internal Medicine physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.
What does this payment reveal about Gregory Evans's relationship with Biogen?
The payment amount is substantial for a single consulting engagement. This $13.5K consulting payment is part of the transparency data reported under the Sunshine Act.
Is this payment amount typical for Internal Medicine?
The payment is specifically tied to consulting services, not research or speaking.
What should patients do after learning about this payment?
Patients should be aware that their physicians may receive payments from pharmaceutical companies for consulting services, which could potentially influence prescribing decisions.
What else should I know about this consulting payment?
The drug Rybelsus is a treatment for diabetes, indicating a focus on metabolic or endocrine conditions within Internal Medicine.
Related Reports
Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.